Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350

The Danger Model: A Renewed Sense of Self

Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205

Tumour-associated macrophages as treatment targets in oncology

Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,157

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520

Immunogenic cell death and DAMPs in cancer therapy

Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Immunogenic cell death in cancer and infectious disease

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798

The integrated stress response

Pakos‐Zebrucka, K., Koryga, I., Mnich, K., Ljujic, M., Samali, A., & Gorman, A. M. (2016) · The EMBO Reports · doi:10.15252/embr.201642195 · Cited by 2,659

PD-L1 expression as a predictive biomarker in cancer immunotherapy

Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291

The immune contexture in cancer prognosis and treatment

Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834

Dysbiosis and the immune system

Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., & Elinav, E. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.7 · Cited by 1,769

Principles of cancer therapy: oncogene and non-oncogene addiction

Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752

DAMP-sensing receptors in sterile inflammation and inflammatory diseases

Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530

Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy

Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,417

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,342

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, É., Cesne, A. L., Zitvogel, L., & Chauffert, B. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,285

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity

Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245

Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I

Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240

Immunogenic death of colon cancer cells treated with oxaliplatin

Tesnière, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apétoh, L., Barault, L., et al. (2009) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,224

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Buqué, A., Chan, T. A.-T., Coukos, G., Demaria, S., Deutsch, É., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,210

History of myeloid-derived suppressor cells

Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

Ohue, Y., & Nishikawa, H. (2019) · Cancer Science · doi:10.1111/cas.14069 · Cited by 1,093

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005

Targeting neoantigens to augment antitumour immunity

Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 971

Gut microbiota modulation of chemotherapy efficacy and toxicity

Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., de Vijver, K. K. V., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 932

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928

Chemotherapy‐induced neutropenia

Crawford, J., Dale, D. C., & Lyman, G. H. (2004) · Cancer · doi:10.1002/cncr.11882 · Cited by 887

Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death

Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848

The Basis of Oncoimmunology

Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death

Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

Bruchard, M., Mignot, G., Dérangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 797

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777

Extracellular ATP and P2 purinergic signalling in the tumour microenvironment

Virgilio, F. D., Sarti, A. C., Falzoni, S., Marchi, E. D., & Adinolfi, E. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 748

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Catani, J. P. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 727

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711

Metronomic chemotherapy: new rationale for new directions

Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 666

Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Barcellos‐Hoff, M. H., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 651

Chemotherapy Use, Performance Status, and Quality of Life at the End of Life

Prigerson, H. G., Bao, Y., Shah, M. A., Paulk, M. E., LeBlanc, T. W., Schneider, B. J., Garrido, M. M., Reid, M. C., Berlin, D., Adelson, K. B., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2378 · Cited by 648

RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8 + T cells

Yatim, N., Jusforgues-Saklani, H., Orozco, S. L., Schulz, O., da Silva, R. B., Sousa, C. R. E., Green, D. R., Oberst, A., & Albert, M. L. (2015) · Science · doi:10.1126/science.aad0395 · Cited by 643

Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy

Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30144-x · Cited by 568

Epigenetic therapy in immune-oncology

Jones, P. A., Ohtani, H., Chakravarthy, A., & Carvalho, D. D. D. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 559

Targeting adenosine for cancer immunotherapy

Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 557

Linking cellular stress responses to systemic homeostasis

Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 556

Caloric restriction mimetics enhance anticancer immunosurveillance

Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E., Levesque, S., Castoldi, F., Jacquelot, N., Yamazaki, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.016 · Cited by 542

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525

TGFβ is a master regulator of radiation therapy-induced antitumor immunity

Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500

Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis

Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474

Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity

Aaes, T. L., Kaczmarek, A., Delvaeye, T., Craene, B. D., Koker, S. D., Heyndrickx, L., Delrue, I., Taminau, J., Wiernicki, B., Groote, P. D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.037 · Cited by 464

Glucocorticoids promote breast cancer metastasis

Obradović, M. M. S., Hamelin, B., Manevski, N., Couto, J. P., Sethi, A., Coissieux, M.-M., Münst, S., Okamoto, R., Kohler, H., Schmidt, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1019-4 · Cited by 462

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452

Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses

Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 451

Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination

Hammerich, L., Marron, T. U., Upadhyay, R., Svensson‐Arvelund, J., Dhainaut, M., Hussein, S., Zhan, Y., Ostrowski, D., Yellin, M. J., Marsh, H. C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0410-x · Cited by 448

Post-traumatic stress disorder and cancer

Cordova, M. J., Riba, M. B., & Spiegel, D. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30014-7 · Cited by 442

An Immunosurveillance Mechanism Controls Cancer Cell Ploidy

Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436

Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death

Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423

Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner

Wanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420

Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response

Fucikova, J. P., Králíková, P., Fialová, A., Brtnický, T., Rob, L., Bartůňková, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 415

PD-1 Restrains Radiotherapy-Induced Abscopal Effect

Park, S. S., Dong, H., Liu, X., Harrington, S. M., Krco, C. J., Grams, M. P., Mansfield, A. S., Furutani, K. M., Olivier, K. R., & Kwon, E. D. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0138 · Cited by 403

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Peters, S., Gettinger, S. N., Johnson, M. L., Janne, P. A., Garassino, M. C., Christoph, D. C., Toh, C., Rizvi, N. A., Chaft, J. E., Carcereny, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9476 · Cited by 401

Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388

Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity

Yang, H., Xia, L., Chen, J., Zhang, S., Martin, V., Li, Q., Lin, S., Chen, J., Calmette, J., Lu, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0566-4 · Cited by 379

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

Le, H. K., Graham, L., Cha, E., Morales, J. K., Manjili, M. H., & Bear, H. D. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.03.015 · Cited by 368

The promise and challenges of immune agonist antibody development in cancer

Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 367

Alternative tumour-specific antigens

Smith, C. C., Selitsky, S. R., Chai, S., Armistead, P. M., Vincent, B. G., & Serody, J. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0162-4 · Cited by 366

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362

Mouse models in oncoimmunology

Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J., & Kroemer, G. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.91 · Cited by 361

Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy

Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apétoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20100269 · Cited by 356

Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination

Le, C. P., Nowell, C. J., Kim-Fuchs, C., Botteri, E., Hiller, J. G., Ismail, H., Pimentel, M. A., Chai, M. G., Karnezis, T., Rotmensz, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms10634 · Cited by 354

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Chen, R., Zinzani, P. L., Lee, H. J., et al. (2019) · Blood · doi:10.1182/blood.2019000324 · Cited by 332

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

Ladoire, S., Arnould, L., Apétoh, L., Coudert, B. P., Martin, F., Chauffert, B., Fumoleau, P., & Ghiringhelli, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4491 · Cited by 322

Natural and therapy-induced immunosurveillance in breast cancer

Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 316

Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin

Garg, A. D., Krysko, D. V., Vandenabeele, P., & Agostinis, P. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1184-2 · Cited by 307

ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death

Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., Krysko, D. V., Mathieu, C., & Agostinis, P. (2013) · Autophagy · doi:10.4161/auto.25399 · Cited by 305

Architecture of metaphase chromosomes and chromosome scaffolds

Earnshaw, W. C., & Laemmli, U. K. (1983) · Journal of Cell Biology · doi:10.1083/jcb.96.1.84 · Cited by 305

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death

Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292

Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy

Chen, G., Chen, Z., Wen, D., Wang, Z., Li, H., Zeng, Y., Dotti, G., Wirz, R. E., & Gu, Z. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917891117 · Cited by 278

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

Garg, A. D., Vandenberk, L., Koks, C., Verschuere, T., Boon, L., Van Gool, S. W., & Agostinis, P. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0105 · Cited by 270

cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity

Wang, Z., Chen, J., Hu, J., Zhang, H., Xu, F., He, W., Wang, X., Li, M., Lu, W., Zeng, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127471 · Cited by 253

eIF2α phosphorylation is pathognomonic for immunogenic cell death

Bezu, L., Sauvat, A., Humeau, J., Gomes-da-Silva, L. C., Iribarren, K., Forveille, S., Garcia, P., Zhao, L., Liu, P., Zitvogel, L., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-017-0044-9 · Cited by 251

Cytosolic DNA Sensing in Organismal Tumor Control

Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250

Non‐Thermal Plasma as a Unique Delivery System of Short‐Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells

Lin, A. G., Gorbanev, Y. Y., Backer, J. D., Loenhout, J. V., Boxem, W. V., Lemière, F., Cos, P., Dewilde, S., Smits, E., & Bogaerts, A. (2019) · Advanced Science · doi:10.1002/advs.201802062 · Cited by 249

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

Fournel, L., Wu, Z., Stadler, N., Damotte, D., Lococo, F., Boulle, G., Ségal-Bendirdjian, E., Bobbio, A., Icard, P., Trédaniel, J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.005 · Cited by 249

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

García-Martínez, E., Gil, G. L., Benito, A. C., González-Billalabeitia, E., Conesa, M. V., García, T., García-Garre, E., Vicente, V., & de la Peña, F. A. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0488-5 · Cited by 236

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 231

Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial

Hiller, J. G., Cole, S. W., Crone, E. M., Byrne, D. J., Shackleford, D. M., Pang, J.-M. B., Henderson, M. A., Nightingale, S. S., Ho, K. M., Myles, P. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2641 · Cited by 223

Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Miyamoto, S., Inoue, H., Nakamura, T., Yamada, M., Sakamoto, C., Urata, Y., Okazaki, T., Marumoto, T., Takahashi, A., Takayama, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3185 · Cited by 222

Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy

Krosl, G., Korbelik, M., & Dougherty, G. J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.108 · Cited by 219

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Grigg, C. M., & Rizvi, N. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0153-x · Cited by 219

Newcastle disease virotherapy induces long‐term survival and tumor‐specific immune memory in orthotopic glioma through the induction of immunogenic cell death

Koks, C., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., Vleeschouwer, S. D., Agostinis, P., Graf, N. M., & Gool, S. V. (2014) · International Journal of Cancer · doi:10.1002/ijc.29202 · Cited by 216

Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression

Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216

Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation

Klein, L., Robey, E. A., & Hsieh, C.-S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0083-6 · Cited by 214

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer

Dosset, M., Vargas, T. R., Lagrange, A., Boidot, R., Végran, F., Roussey, A., Chalmin, F., Dondaine, L., Paul, C., Joseph, E. L. M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433981 · Cited by 212

Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer

Chang, C.-W., Lee, H., Li, L.-H., Chiau, J. C., Wang, T.-E., Chuang, W.-H., Chen, M., Wang, H.-Y., Shih, S., Liu, C.-Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020386 · Cited by 210

Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.

Korbelik, M., & Dougherty, G. J. (1999) · PubMed · Cited by 209

Calreticulin Expression in Human Non–Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis

Fucikova, J. P., Becht, É., Iribarren, K., Goc, J., Remark, R., Damotte, D., Alifano, M., Devi-Marulkar, P., Biton, J., Germain, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1142 · Cited by 206

Nanosecond-Pulsed DBD Plasma-Generated Reactive Oxygen Species Trigger Immunogenic Cell Death in A549 Lung Carcinoma Cells through Intracellular Oxidative Stress

Lin, A. G., Truong, B., Patel, S. H., Kaushik, N. K., Choi, E. H., Fridman, G., Fridman, A., & Miller, V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050966 · Cited by 203

Measles virus causes immunogenic cell death in human melanoma

Donnelly, O., Errington‐Mais, F., Steele, L. P., Hadac, E. M., Jennings, V. A., Scott, K. J., Peach, H., Phillips, R. M., Bond, J., Pandha, H., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.205 · Cited by 201

Modulation of regulatory T cell function and stability by co-inhibitory receptors

Lucca, L. E., & Dominguez‐Villar, M. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0296-3 · Cited by 197

Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

Segovia, C., José‐Eneriz, E. S., Munera-Maravilla, E., Martínez‐Fernández, M., Gárate, L., Miranda, E., Vilas‐Zornoza, A., Lodewijk, I., Rubio, C., Segrelles, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0499-y · Cited by 191

Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy

Yang, H., Ma, Y., Chen, G., Zhou, H., Yamazaki, T., Klein, C., Pietrocola, F., Vacchelli, E., Souquère, S., Sauvat, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149673 · Cited by 188

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer

Ghaffari, A., Peterson, N. T., Khalaj, K., Vitkin, N., Robinson, A. G., Francis, J., & Koti, M. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0188-5 · Cited by 188

Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes

Wong, D. Y. Q., Ong, W. W. F., & Ang, W. H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500934 · Cited by 186

Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles

Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183

High hydrostatic pressure induces immunogenic cell death in human tumor cells

Fucikova, J. P., Moserova, I. K., Truxová, I., Heřmanová, I., Vančurová, I., Partlová, S., Fialová, A., Sojka, L., Cartron, P., Houška, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28766 · Cited by 180

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer

Park, S. J., Ye, W., Xiao, R., Silvin, C. J., Padget, M. R., Hodge, J. W., Waes, C. V., & Schmitt, N. C. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.016 · Cited by 179

Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients

Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1259 · Cited by 170

Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus

Diaconu, I., Cerullo, V., Hirvinen, M., Escutenaire, S., Ugolini, M., Pesonen, S. K., Bramante, S., Parviainen, S., Kanerva, A., Loskog, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2975 · Cited by 167

Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer

Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 164

Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells

Azzariti, A., Iacobazzi, R. M., Fonte, R., Porcelli, L., Gristina, R., Favia, P., Fracassi, F., Trizio, I., Silvestris, N., Guida, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40637-z · Cited by 164

The functional significance of epitope spreading and its regulation by co‐stimulatory molecules

Vanderlugt, C. L., Begolka, W. S., Neville, K. L., Katz‐Levy, Y., Howard, L. M., Eagar, T. N., Bluestone, J. A., & Miller, S. D. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01208.x · Cited by 163

Classification of Chemotherapeutic Agents Based on Their Differential In vitro Effects on Dendritic Cells

Tanaka, H., Matsushima, H., Mizumoto, N., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1101 · Cited by 162

Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer

Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00402 · Cited by 159

Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors

Lin, A. G., Xiang, B., Merlino, D. J., Baybutt, T. R., Sahu, J., Fridman, A., Snook, A. E., & Miller, V. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484978 · Cited by 156

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

Reck, M., Ciuleanu, T.-E., Dols, M. C., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9501 · Cited by 153

The oncolytic peptide LTX-315 triggers immunogenic cell death

Zhou, H., Forveille, S., Sauvat, A., Yamazaki, T., Senovilla, L., Ma, Y., Liu, P., Yang, H., Bezu, L., Müller, K., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.47 · Cited by 151

Trial watch: dendritic cell vaccination for cancer immunotherapy

Sprooten, J., Ceusters, J., Coosemans, A., Agostinis, P., Vleeschouwer, S. D., Zitvogel, L., Kroemer, G., Galluzzi, L., & Garg, A. D. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638212 · Cited by 151

The immunological effects of taxanes

Chan, O. T. M., & Yang, L. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620000122 · Cited by 148

Prognostic significance of HLA class I expression in osteosarcoma defined by anti‐pan HLA class I monoclonal antibody, EMR8‐5

Tsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148

Combining chemotherapy with PD-1 blockade in NSCLC

Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.003 · Cited by 147

Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients

Rodriguez-Ruiz, M. E., Buqué, A., Hensler, M., Chen, J., Bloy, N., Petroni, G., Sato, A., Yamazaki, T., Fucikova, J., & Galluzzi, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655964 · Cited by 147

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes

Hoecke, L. V., Lint, S. V., Roose, K., Parys, A. V., Vandenabeele, P., Grooten, J., Tavernier, J. H., Koker, S. D., & Saelens, X. (2018) · Nature Communications · doi:10.1038/s41467-018-05979-8 · Cited by 146

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages

Buhtoiarov, I. N., Sondel, P. M., Wigginton, J. M., Buhtoiarova, T. N., Yanke, E. M., Mahvi, D. A., & Rakhmilevich, A. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03357.x · Cited by 143

Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms

Wardill, H. R., Gibson, R. J., Sebille, Y. Z. A. V., Secombe, K. R., Coller, J. K., White, I. A., Manavis, J., Hutchinson, M. R., Staikopoulos, V., Logan, R. M., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0990 · Cited by 143

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

Bommareddy, P. K., Zloza, A., Rabkin, S. D., & Kaufman, H. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1591875 · Cited by 143

Chemotherapy-induced neuroinflammation is associated with disrupted colonic and bacterial homeostasis in female mice

Loman, B. R., Jordan, K. R., Haynes, B., Bailey, M. T., & Pyter, L. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-52893-0 · Cited by 143

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., Li, J., Wang, X., Gao, S., Qian, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2948 · Cited by 142

CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy

Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Catani, J. P. P., Duret, H., Teng, M. W. L., Kepp, O., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1265 · Cited by 142

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer

Takeuchi, S., Baghdadi, M., Tsuchikawa, T., Wada, H., Nakamura, T., Abe, H., Nakanishi, S., Usui, Y., Higuchi, K., Takahashi, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2921 · Cited by 141

Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set

Sukkurwala, A. Q., Adjemian, S., Senovilla, L., Michaud, M., Spaggiari, S., Vacchelli, E., Baracco, E. E., Galluzzi, L., Zitvogel, L., Kepp, O., et al. (2014) · OncoImmunology · doi:10.4161/onci.28473 · Cited by 141

First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro

Wernitznig, D., Kiakos, K., Favero, G. D., Harrer, N. E., Machat, H., Oßwald, A., Jakupec, M. A., Wernitznig, A., Sommergruber, W., & Keppler, B. K. (2019) · Metallomics · doi:10.1039/c9mt00051h · Cited by 140

Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine

Chen, H., Wang, P.-H., Chen, S.-S., Wen, C.-C., Chen, Y., Yang, W., & Yang, N. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1258-9 · Cited by 138

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells

Nejad, E. B., van der Sluis, T. C., van Duikeren, S., Yagita∥, H., Janssen, G. M. C., van Veelen, P. A., Melief, C. J. M., van der Burg, S. H., & Arens, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0881 · Cited by 137

Pro-necrotic molecules impact local immunosurveillance in human breast cancer

Stoll, G., Ma, Y., Yang, H., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1299302 · Cited by 137

Antineoplastic Agents and the Associated Myelosuppressive Effects

Barreto, J. N., McCullough, K. B., Ice, L. L., et al. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014546108 · Cited by 136

Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1–PD-L1 Axis

Ding, Z., Lu, X., Yu, M., Lemos, H. D. P., Huang, L., Chandler, P., Liu, K., Walters, M. J., Krasinski, A., Mack, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3596 · Cited by 135

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

Fucikova, J., Truxova, I., Hensler, M., Becht, E., Kasikova, L., Moserova, I., Vosahlikova, S., Klouckova, J., Church, S. E., Cremer, I., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731737 · Cited by 135

Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation

Tanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1106 · Cited by 134

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Schaer, D. A., Geeganage, S., Amaladas, N., Lu, Z. H., Rasmussen, E. R., Sonyi, A., Chin, D., Capen, A., Li, Y., Meyer, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0433 · Cited by 132

Immunovirotherapy with measles virus strains in combination with anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment

Hardcastle, J. J., Mills, L., Malo, C. S., Jin, F., Kurokawa, C., Geekiyanage, H., Schroeder, M. A., Sarkaria, J. N., Johnson, A. J., & Galanis, E. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now179 · Cited by 129

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

Bugaut, H., Bruchard, M., Berger, H., Dérangère, V., Odoul, L., Euvrard, R., Ladoire, S., Chalmin, F., Végran, F., Rébé, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065181 · Cited by 127

Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells

Liu, M., Thomas, S. L., DeWitt, A. K., Zhou, W., Madaj, Z. B., Ohtani, H., Baylin, S. B., Liang, G., & Jones, P. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3953 · Cited by 127

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells

Loenhout, J. V., Flieswasser, T., Boullosa, L. F., Waele, J. D., Audenaerde, J. R. M. V., Marcq, E., Jacobs, J., Lin, A. G., Lion, E., Dewitte, H., et al. (2019) · Cancers · doi:10.3390/cancers11101597 · Cited by 122

Immunosuppression by Mutated Calreticulin Released from Malignant Cells

Liu, P., Zhao, L., Loos, F., Marty, C., Xie, W., Martins, I., Lachkar, S., Qu, B., Waeckel-Énée, E., Plo, I., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.004 · Cited by 122

PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models

Yamazaki, T., Buqué, A., Ames, T. D., & Galluzzi, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1721810 · Cited by 121

Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death

Nuccitelli, R., McDaniel, A. E., Anand, S., Cha, J., Mallon, Z. O., Berridge, J. C., & Uecker, D. R. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0234-5 · Cited by 120

Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus

Gomes-da-Silva, L. C., Zhao, L., Bezu, L., Zhou, H., Sauvat, A., Liu, P., Durand, S., Leduc, M., Souquère, S., Loos, F., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798354 · Cited by 119

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Creelan, B., & Antonia, S. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0182-8 · Cited by 119

TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer

Fucikova, J. P., Raková, J., Hensler, M., Kašíková, L., Belicova, L., Hladíková, K., Truxová, I., Škapa, P., Laco, J., Pecen, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4175 · Cited by 119

Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo

Tongu, M., Harashima, N., Monma, H., Inao, T., Yamada, T., Kawauchi, H., & Harada, M. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1343-0 · Cited by 118

The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer

Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1154244 · Cited by 117

Combination of chemotherapy and physical plasma elicits melanoma cell death via upregulation of SLC22A16

Sagwal, S. K., Pasqual-Melo, G., Bodnar, Y., Gandhirajan, R. K., & Bekeschus, S. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1221-6 · Cited by 117

Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release

Korbelik, M., Zhang, W., & Merchant, S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1047-x · Cited by 115

Dominant Role of the Gut Microbiota in Chemotherapy Induced Neuropathic Pain

Ramakrishna, C., Corleto, J., Ruegger, P. M., Logan, G. D., Peacock, B. B., Mendonca, S., Yamaki, S., Adamson, T. W., Ermel, R. W., McKemy, D. D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56832-x · Cited by 108

Nanoelectroablation of Murine Tumors Triggers a CD8-Dependent Inhibition of Secondary Tumor Growth

Nuccitelli, R., Berridge, J. C., Mallon, Z. O., Kreis, M., Athos, B., & Nuccitelli, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134364 · Cited by 106

Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components

Lin, T.-J., Lin, H.-T., Chang, W.-T., Pradeep Mitapalli., S., Hsiao, P., Yin, S., & Yang, N. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0435-9 · Cited by 103

Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface–Associated Calreticulin

Dudek-Perić, A. M., Ferreira, G. B., Muchowicz, A., Wouters, J., Prada, N., Martin, S., Kiviluoto, S., Winiarska, M., Boon, L., Mathieu, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2089 · Cited by 102

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

Shin, J., Chung, J.-H., Kim, S. H., Lee, K. S., Suh, K. J., Lee, J. Y., Kim, J., Lee, J., Kim, J.-W., Kim, Y.-J., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.537 · Cited by 102

Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma

Orecchioni, S., Talarico, G., Labanca, V., Calleri, A., Mancuso, P., & Bertolini, F. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0076-z · Cited by 101

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

Yamazaki, T., Pitt, J. M., Vétizou, M., Marabelle, A., Flores, C., Rekdal, Ø., Kroemer, G., & Zitvogel, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.35 · Cited by 100

Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress

Humeau, J., Sauvat, A., Cerrato, G., Xie, W., Loos, F., Iannantuoni, F., Bezu, L., Lévesque, S., Paillet, J., Pol, J. G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911622 · Cited by 100

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma

Adam, J., Louvet, E., Sourisseau, T., Dorvault, N., Bernard, M., Maingot, E., Faivre, L., Kuo, M.-S., Boissier, É., Dessoliers, M.-C., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000257 · Cited by 96

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression

Korbelik, M., Stott, B., & Sun, J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604059 · Cited by 95

Extracorporeal photochemotherapy induces bona fide immunogenic cell death

Tatsuno, K., Yamazaki, T., Hanlon, D. J., Han, P., Robinson, E., Sobolev, O., Yurter, A., Rivera-Molina, F. E., Arshad, N., Edelson, R. L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1819-3 · Cited by 94

Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody

Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003477 · Cited by 91

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Conroy, J. M., Pabla, S., Nesline, M., Glenn, S. T., Papanicolau‐Sengos, A., Burgher, B., Andreas, J., Giamo, V., Wang, Y., Lenzo, F. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0489-5 · Cited by 90

Human regulatory T cells lack the cyclophosphamide‐extruding transporter ABCB 1 and are more susceptible to cyclophosphamide‐induced apoptosis

Dimeloe, S., Frick, C., Fischer, M., Gubser, P. M., Razik, L., Bantug, G. R., Ravon, M., Langenkamp, A., & Hess, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201444879 · Cited by 89

Immunological tolerance: Danger – pathogen on the premises!

Janeway, C. A., Goodnow, C. C., & Medzhitov, R. M. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00531-6 · Cited by 89

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy

Hemminki, O., Parviainen, S., Juhila, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2901 · Cited by 88

Autophagy in major human diseases

Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445

Rational combinations of targeted cancer therapies: background, advances and challenges

Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269

Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms

Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237

Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators

Debele, T. A., Yeh, C.-F., & Su, W. (2020) · Cancers · doi:10.3390/cancers12123773 · Cited by 86

B7-H3/CD276: An Emerging Cancer Immunotherapy

Zhou, W.-T., & Jin, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701006 · Cited by 303

pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review

Yan, Y., & Ding, H. (2020) · Nanomaterials · doi:10.3390/nano10081613 · Cited by 113

New opportunities for nanoparticles in cancer immunotherapy

Park, W., Heo, Y.-J., & Han, D. K. (2018) · Biomaterials Research · doi:10.1186/s40824-018-0133-y · Cited by 224

Nanotechnology-Based Bacterial Immunotherapy

Arya, R. K. K., Sati, D., Bisht, D., & Keservani, R. K. (2022) · Springer eBooks · doi:10.1007/978-981-19-2507-8_1 · Cited by 2